3654 results for «444»
3654 results
The continuum of valvular heart disease: a lifetime management approach
21 May 2026 – From EuroPCR 2026
This session offers a comprehensive perspective on valvular heart disease through the lens of lifetime management, highlighting the need for strategic planning across aortic, mitral, and tricuspid interventions, illustrating how treating one valve can influence the progression and management of others. Gain insights into optimal timing...
DCB in contemporary PCI: evidence, technique and physiology-guided decision-making
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the evolving role of drug-coated balloons (DCB) in contemporary PCI, highlighting how growing clinical evidence, refined procedural strategies and physiology-guided tools are reshaping everyday practice.
The discussion reviews the latest data supporting DCB use, including long-term outcomes from major registries and trials...
Navigating high-thrombus burden in ACS: precision aspiration thrombectomy with CAT RX
21 May 2026 – From EuroPCR 2026
This session explores the challenges of managing high thrombus burden in patients with acute coronary syndromes (ACS), with a focus on precision aspiration thrombectomy using the CAT RX device. Through case-based examples, it provides practical insights into procedural techniques and examines the role of CAT RX...
Evolving bifurcation treatment practices: DCB, angio-based FFR and side branch optimisation
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the evolving landscape of bifurcation PCI, focusing on drug-coated balloon (DCB) strategies, angio-based fractional flow reserve (FFR) and side branch optimisation. It highlights how new evidence and physiology-guided tools are reshaping decision-making in this complex lesion subset.
Discussions include insights from the...
Artificial intelligence-driven precision therapy for TAVI: progress and practice in China
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the integration of artificial intelligence into precision therapy for TAVI in China, highlighting its growing role in procedural planning, optimisation and outcome prediction.
Through case-based discussion, it shows how AI-enabled tools can simulate valve deployment and visualise post-TAVR results, supporting more precise...
When less is better - Differentiated therapies to safely achieve TR 0-1+
19 May 2026 – From EuroPCR 2026
Therapeutic goals in tricuspid regurgitation are evolving, with increasing emphasis on achieving near-complete elimination of regurgitation (TR 0–1+) through differentiated transcatheter strategies.
This EuroPCR 2026 session explores how transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR) can be used in a complementary way to reach...
Real world practice inspiring new evidence generation in structural heart
21 May 2026 – From EuroPCR 2026
This LIVE case session showcases real-world clinical practice driving new evidence in structural heart interventions, with a focus on TAVI. It features expert insights into pre-procedural imaging and sizing, treatment strategies, procedural techniques, and post-procedural management. The session also introduces the novel Myval Octapro+ transcatheter heart...
The microcirculation: the next frontier in coronary practice
18 May 2026 – From EuroPCR 2026
Delve into the complexities of coronary microcirculation and its clinical implications. This session highlighted advanced diagnostic techniques such as bolus and continuous thermodilution, the interpretation of microvascular resistance reserve, and practical guidance on establishing a high-impact ANOCA clinic to manage microvascular angina and coronary dysfunction.
Impella percutaneous ventricular assist device malrotation in social media: a call to action
20 Apr 2023
The data from this study suggest that, from a SoMe perspective, correct Impella orientation is often overlooked, and that Impella malrotation is a common issue in real-world clinical practice, potentially associated with relevant complications.
Author
Author
Author
Author
Author
Elixir Medical completes enrollment in BIOADAPTOR randomized controlled trial of Dynamx Coronary Bioadaptor System
15 Feb 2022
The FLAVOUR Randomized Clinical Trial: Comparison of Fractional Flow Reserve-guided and Intravascular Ultrasound-guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Stenosis
22 Mar 2022
Daniele Giacoppo analyses the main results of the FLAVOUR trial which were presented by Bon-Kwon Koo, from Seoul National University Hospital, South Korea at the American College of Cardiology 2022.
Author
OPTION – Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation
08 Nov 2022
Ali Nazmi Calik provides his take on OPTION, which was presented during AHA 2022 in Chicago.
Author
New insights from the early and delayed aortic valve replacement implant patients: a sub-analysis of the Early TAVR trial
29 Mar 2025
Luigi Biasco provides his take on a sub-analysis of the Early TAVR trial about the early and delayed aortic valve replacement implant patients presented by Philippe Genereux at ACC.25 in Chicago.
Author
The effectiveness and safety of a planned investment procedure in high-risk chronic total occlusions - The INVEST CTO single arm study
03 Nov 2025
Kalaivani Mahadevan and Sofia Papadopoulou provide their take on the INVEST CTO trial, presented by Anja Oksnes at TCT 2025, in San Francisco.
Author
Author
